ClinicalTrials.gg
Not yet recruitingNCT07462130Updated Mar 10, 2026

An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED)

A Phase 1/2 interventional study of NTB003 and NTB003 in Thyroid Eye Disease, sponsored by Nanjing Chia-tai Tianqing Pharmaceutical. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Nanjing Chia-tai Tianqing Pharmaceutical (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Multicentre, Phase Ib/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of NTB003 in Participants with Thyroid Eye Disease

02

Conditions studied

  • Thyroid Eye Disease

Browse trials for

03

In context

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

This study's planned enrollment of 74 is above the median of 63 across 146 interventional studies indexed under Graves Ophthalmopathy.

Browse Graves Ophthalmopathy studies →

Lead sponsor

Nanjing Chia-tai Tianqing Pharmaceutical is the lead sponsor of 19 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Male or female subjects aged 18-75 years who have signed . 2.Body weight between 40 kg and 100 kg. 3.Clinical diagnosis of thyroid eye disease (TED): Active thyroid eye disease (TED): at least one eye with a CAS ≥ 3 and proptosis ≥ 3 mm above the in that eye, and the subject's first onset of TED ocular signs/symptoms (by subject report or medical records) occurred within 1 year prior to first study drug administration; Chronic Thyroid Eye Disease (TED) : bilateral CAS \< 3, and the first onset of TED ocular signs/symptoms (by subject report or medical records) occurred > 12 months prior to first study drug administration.

    4.Subjects clinically graded as having moderate-to-severe TED per the European Group on Graves' Orbitopathy (EUGOGO) classification at screening and baseline, typically accompanied by proptosis ≥ 3 mm above the upper limit of normal (normal range 12-16 mm). In addition, subjects should have one or more of the following features: eyelid retraction ≥ 2 mm, moderate or severe soft-tissue involvement, or intermittent/persistent diplopia.

    5.Do not require immediate ophthalmic surgical intervention and no corrective surgery or orbital radiotherapy is planned during the study.

    6.Euthyroid with underlying thyroid disease controlled, or mild hypothyroidism or hyperthyroidism (defined as screening free triiodothyronine [FT3] and free thyroxine [FT4] levels \< 50% above or below the normal limits).

    7.Subjects of must agree to use effective during the trial and for at least 6 months after the last dose. Acceptable methods include complete abstinence, barrier contraception (e.g., condom), tubal ligation, intrauterine device, hormonal contraception (oral contraceptives, injections, transdermal patch, vaginal ring, or implant), or partner vasectomy.

    8.Female subjects of childbearing potential must have a negative pregnancy test within 7 days prior to first study drug administration and must not be breastfeeding.

Exclusion criteria

Exclusion Criteria:

  • 1. A reduction of ≥2 points in the CAS value or a reduction of ≥2 mm in proptosis in the study eye from the screening assessment period to study baseline period.

    2.Within 6 months prior to screening, decrease in best corrected visual acuity (BCVA) attributable to TED optic neuropathy, defined as a loss of two lines of acuity, new visual field defect, or color vision defect secondary to optic nerve involvement.

    3.Corneal abnormalities that, in the investigator's opinion, could affect efficacy assessments.

    4.Prior or planned orbital radiotherapy or ocular surgery for TED, including orbital decompression, strabismus surgery, eyelid surgery, or similar procedures.

    5.History of hearing impairment, or abnormal pure-tone audiometry at screening.

    6.History of inflammatory bowel disease, or clinically suspected inflammatory bowel disease (e.g., unexplained diarrhea with or without blood or rectal bleeding plus abdominal pain or cramping for >4 weeks; endoscopic or imaging evidence of enteritis/colitis without other explanation).

    7.Prior treatment with IGF-1 or IGF-1R-related agents. 8.Poorly controlled diabetes at screening. 9.Poorly controlled hypertension at screening. 10. or ALT > 3×; or serum creatinine > 1.5×ULN; or count \< 100 × 10\^9/L; or \< 2.0 × 10\^9/L at screening:.

    11.Active hepatitis, defined as positive with detectable HBV DNA above the local laboratory's lower limit of detection; or antibody positive.

    12.History of infection or positive HIV antibody test. 13.Any active or suspected bacterial, viral, or fungal infection (e.g., severe common cold, viral syndrome, influenza-like illness) requiring intravenous antimicrobial therapy within 4 weeks prior to first dose.

    14.Receipt of, or planned receipt during the study of, live or within 4 weeks prior to first dose.

    15.Use of selenium, biotin, or traditional Chinese medicine therapies for TED (e.g., triptolide-containing compounds, Epimedium, polygonum cuspidatum, lotus seed heart, acupuncture, etc.) within 3 weeks prior to first dose or planned use during the study; combination multivitamins containing selenium and/or vitamins are permitted.

    16.Use of oral or intravenous systemic for any reason within 4 weeks prior to first dose; or topical ophthalmic glucocorticoid eye drops/ointments for TED within 7 days prior to first dose. Use of topical glucocorticoids for non-TED indications (e.g., dermatologic conditions) before or during the study is allowed.

    17.Use of oral or intravenous nonsteroidal for TED (e.g., mycophenolate mofetil, cyclosporine, methotrexate, azathioprine, etc.) within 4 weeks prior to first dose; or topical ophthalmic nonsteroidal immunosuppressant eye drops for TED within 7 days prior to first dose.

    18.Periocular/orbital steroid injection within 3 months prior to first dose. 19.Treatment with anti-CD20 antibodies, interleukin-6 antibodies, or other biologic agents for TED within 3 months prior to first dose.

    20.Botulinum toxin (or other chemical denervation agents) treatment for TED within 3 months prior to first dose.

    21.Participation in another interventional clinical trial within 3 months prior to first dose.

    22.Known or suspected allergy to the product or any of its components, or prior history of to other antibody drugs.

    23.Any prior or concomitant disease or condition that, in the investigator's judgment, may interfere with trial compliance or affect evaluation of trial results (e.g., psychiatric disorders, recent acute cardiovascular or cerebrovascular events, history of treated or untreated within 5 years), or any other condition deemed by the investigator to make the subject unsuitable for participation.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Ib study : NTB003 dose 1

    Drug: NTB003

  • Experimental
    Cohort 2

    Ib study :NTB003 dose 2

    Drug: NTB003

  • Experimental
    Cohort 3

    Ib study :NTB003 dose 3

    Drug: NTB003

  • Experimental
    Cohort 4

    II study :SC injection of dose of NTB003 or placebo

    Drug: NTB003 and Placebo

Interventions

  • DrugNTB003

    NTB003 dose 1 administered SC injection every 4 weeks.

  • DrugNTB003

    NTB003 dose 2 administered SC injection every 4 weeks.

  • DrugNTB003

    NTB003 dose 3 administered SC injection every 4 weeks.

  • DrugNTB003 and Placebo

    Drug:NTB003 subcutaneous injection Drug: Placebo subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Proptosis Responder Rate in the study eye

    Proptosis Responder Rate in the study eye (i.e., reduction of proptosis of ≥ 2 mm from baseline \[without a corresponding increase of ≥ 2 mm in the fellow eye\] as measured by exophthalmometer)

    Time frame: Week 12

Secondary outcomes

  1. Change from baseline in proptosis in the study eye

    Change from baseline in proptosis in the study eye as measured by exophthalmometer

    Time frame: Baseline, up to Week 24

  2. Change from baseline in CAS

    Change from baseline in Clinical Activity Score (CAS) in the study eye;

    Time frame: Baseline, up to Week 24

  3. Overall Responder Rate

    Overall Responder Rate comprising Proptosis Responder Rate as measured by exophthalmometer and Clinical Activity Responder Rate in the study eye

    Time frame: up to Week 24

  4. Diplopia response rate

    The percentage of subjects with a reduction in diplopia severity by ≥1 grade.

    Time frame: up to Week 24

  5. Diplopia Resolution Rate

    reduction in Gorman Subjective Diplopia Score to 0 from baseline for participants with baseline Gorman Subjective Diplopia Score \>0

    Time frame: up to Week 24

  6. Change in Quality of Life (GO-QOL) Scores

    Time frame: up to Week 24

  7. Pharmacokinetic parameters: Cmax

    Maximum blood concentration of NTB003

    Time frame: Up to Week 32

  8. Pharmacodynamic for NTB003:Summarize IGF-1 measurements at baseline and at each post-dose time point, and compile the changes at each time point relative to baseline.

    Time frame: Up to Week 32

  9. Anti-NTB003 antibody (ADA) incidence

    Time frame: Up to Week 32

  10. Pharmacokinetic parameters: AUC

    The area under the concentration versus time curve of NTB003.

    Time frame: up to 32 Week

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for May 2027, 14 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Mar 10, 2026
StartEst.
Mar 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Mar 30, 2028
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07462130
Responsible party
Sponsor
First posted
Mar 10, 2026
Start date
Mar 1, 2026 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Mar 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion